Targeted T cell therapy for metastatic lung cancer with mutated KRAS
Official title: Project 2: Treating metastatic lung cancer by targeting mutated KRAS with engineered T cells
Funded at Fred Hutchinson Cancer Center · NIH-11397778 · Data updated 2026-11-12
A personalized therapy uses engineered T cells to attack KRAS-mutated metastatic non-small cell lung cancer in patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2019 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $423,020 |
| NIH project number | 5P50CA228944-08 |
| Project ID | NIH-11397778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic non-small cell lung cancer harboring specific KRAS mutations who are eligible for T cell-based therapy.
✕Less likely to help
Patients without the relevant KRAS mutation or those unable to safely receive cellular therapies may not benefit.
What this research studies
This project aims to treat advanced lung cancer by using a patient’s own immune cells that are engineered to recognize and attack cancer cells with KRAS mutations. The approach combines immunotherapy with precision targeting to overcome resistance to standard treatments. Researchers at Fred Hutchinson Cancer Center will prepare and infuse these engineered T cells into eligible patients and monitor responses and safety over time. The work builds on lessons from other cancers where tumor-reactive T cells have shown strong activity in boosting anti-tumor immunity.
Why it matters
Potential benefit: If successful, patients could experience stronger, longer-lasting control of their cancer with fewer side effects than some standard therapies.
How similar studies have gone: Engineered T cell therapies have shown promise in melanoma and other cancers, with ongoing exploration in lung cancer.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Greenberg, Philip D — Fred Hutchinson Cancer Center
- Study coordinator: Greenberg, Philip D
Related research
Other NIH-funded projects on the same topics.
-
ECM-targeted theranostic treatment for metastatic lung cancer
A new therapy aims to deliver cancer-fighting agents directly to the tumor environment in people with metastatic lung cancer.
-
Supportive Care for Lung Cancer Patients with Targeted Therapy
A patient-facing program tests a palliative care approach tailored for people living with oncogene-driven metastatic lung cancer to help with uncertainty, self-care, and discussions about goals and values.
-
LiveWell — DBT skills training for people living with metastatic lung cancer
This is an eight-session, one-on-one online program that teaches Dialectical Behavior Therapy skills to help people living with metastatic lung cancer handle distress, symptoms, and relationships.
-
Engineered T cells that target KRAS-mutated metastatic lung cancer
This project uses specially engineered immune cells to try to find and kill metastatic lung cancers that have KRAS gene mutations.
-
Using aerosolized therapy to treat metastatic lung cancer
This study is exploring a new way to treat metastatic lung cancer by using a special inhaled therapy that may help wake up genes in cancer cells, and it's designed for patients looking for more effective treatment options.
-
Improving care for patients with advanced lung cancer using personalized approaches
This study is looking to improve support for people with metastatic lung cancer who have certain genetic mutations by testing a new way to help them feel more comfortable and make better decisions about their care, based on what they and their doctors think is important.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.